BACKGROUND: In BMS Study 045, once-daily (QD) atazanavir/ritonavir (ATV/RTV) demonstrated comparable efficacy and safety to twice-daily (BID) lopinavir/ritonavir (LPV/RTV) over 48 weeks in treatment-experienced patients. Results of extended follow-up to 96 weeks are presented. METHODS: BMS Study 045 was an open-label, randomized, multi-national trial of HIV-infected patients with virologic failure on two or more prior HAART regimens designed to evaluate the efficacy and safety of ATV/RTV (300/100 mg) QD and LPV/RTV (400/100 mg) BID, each with tenofovir (300 mg) QD and one nucleoside reverse transcriptase inhibitor. The primary efficacy measure was the time-averaged difference (TAD) in reduction in HIV RNA from baseline. Secondary objectives included evaluation of safety and plasma lipid levels through week 96. RESULTS: Over 96 weeks, the ATV/RTV regimen demonstrated similar virologic efficacy to the LPV/RTV regimen. Mean reductions from baseline in HIV RNA were -2.29 and -2.08 log10 copies/ml, respectively [TAD (97.5% confidence interval): 0.14 log10 copies/ml (-0.13, 0.41)]. The LPV/RTV regimen resulted in significant increases in total cholesterol (+9%) and fasting triglycerides (+30%) in comparison with the ATV/RTV regimen, which demonstrated decreases in these parameters [-7 and -2%, respectively, (P < 0.0001)]. Grade 2-4 diarrhoea occurred less frequently in ATV/RTV patients (3%) in comparison with LPV/RTV patients (13%) (P < 0.01). Grade 3-4 elevations in bilirubin were more common in ATV/RTV patients (53%) than LPV/RTV patients (< 1%) (P < 0.0001), with no resulting discontinuations. CONCLUSIONS: Regimens containing once-daily ATV/RTV demonstrated comparable efficacy and safety, with significant reductions in total cholesterol and fasting triglycerides and improved gastrointestinal-tolerability in comparison with twice-daily regimens containing LPV/RTV over 96 weeks in treatment-experienced patients.
RCT Entities:
BACKGROUND: In BMS Study 045, once-daily (QD) atazanavir/ritonavir (ATV/RTV) demonstrated comparable efficacy and safety to twice-daily (BID) lopinavir/ritonavir (LPV/RTV) over 48 weeks in treatment-experienced patients. Results of extended follow-up to 96 weeks are presented. METHODS: BMS Study 045 was an open-label, randomized, multi-national trial of HIV-infectedpatients with virologic failure on two or more prior HAART regimens designed to evaluate the efficacy and safety of ATV/RTV (300/100 mg) QD and LPV/RTV (400/100 mg) BID, each with tenofovir (300 mg) QD and one nucleoside reverse transcriptase inhibitor. The primary efficacy measure was the time-averaged difference (TAD) in reduction in HIV RNA from baseline. Secondary objectives included evaluation of safety and plasma lipid levels through week 96. RESULTS: Over 96 weeks, the ATV/RTV regimen demonstrated similar virologic efficacy to the LPV/RTV regimen. Mean reductions from baseline in HIV RNA were -2.29 and -2.08 log10 copies/ml, respectively [TAD (97.5% confidence interval): 0.14 log10 copies/ml (-0.13, 0.41)]. The LPV/RTV regimen resulted in significant increases in total cholesterol (+9%) and fasting triglycerides (+30%) in comparison with the ATV/RTV regimen, which demonstrated decreases in these parameters [-7 and -2%, respectively, (P < 0.0001)]. Grade 2-4 diarrhoea occurred less frequently in ATV/RTVpatients (3%) in comparison with LPV/RTVpatients (13%) (P < 0.01). Grade 3-4 elevations in bilirubin were more common in ATV/RTVpatients (53%) than LPV/RTVpatients (< 1%) (P < 0.0001), with no resulting discontinuations. CONCLUSIONS: Regimens containing once-daily ATV/RTV demonstrated comparable efficacy and safety, with significant reductions in total cholesterol and fasting triglycerides and improved gastrointestinal-tolerability in comparison with twice-daily regimens containing LPV/RTV over 96 weeks in treatment-experienced patients.
Authors: Pyoeng Gyun Choe; Wan Beom Park; Jin Su Song; Nak-Hyun Kim; Kyoung-Ho Song; Sang Won Park; Hong Bin Kim; Nam Joong Kim; Myoung-don Oh Journal: J Korean Med Sci Date: 2010-09-17 Impact factor: 2.153
Authors: Francesc Vidal; Joan Carles Domingo; Jordi Guallar; Maria Saumoy; Begoña Cordobilla; Rainel Sánchez de la Rosa; Marta Giralt; Maria Luisa Alvarez; Miguel López-Dupla; Ferran Torres; Francesc Villarroya; Tomas Cihlar; Pere Domingo Journal: Antimicrob Agents Chemother Date: 2006-08-28 Impact factor: 5.191
Authors: Michael D April; John J Chiosi; A David Paltiel; Paul E Sax; Rochelle P Walensky Journal: J Gen Intern Med Date: 2011-02-01 Impact factor: 5.128
Authors: Edward P Acosta; Michelle A Kendall; John G Gerber; Beverly Alston-Smith; Susan L Koletar; Andrew R Zolopa; Sangeeta Agarwala; Michael Child; Richard Bertz; Lara Hosey; David W Haas Journal: Antimicrob Agents Chemother Date: 2007-06-18 Impact factor: 5.191
Authors: Katherine Tassiopoulos; Paige L Williams; George R Seage; Marilyn Crain; James Oleske; John Farley Journal: J Acquir Immune Defic Syndr Date: 2008-04-15 Impact factor: 3.731
Authors: Pamela P Pei; Milton C Weinstein; X Cynthia Li; Michael D Hughes; A David Paltiel; Taige Hou; Robert A Parker; Melanie R Gaynes; Paul E Sax; Kenneth A Freedberg; Bruce R Schackman; Rochelle P Walensky Journal: HIV Clin Trials Date: 2015-12-11